A Phase 1, Open-label, Randomized Crossover Study, in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 500-mg Dose of JNJ-53718678 Administered as (an) Oral Concept Formulation(s) Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of (an) Oral Concept Formulation(s)
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 Jul 2017 Planned number of patients changed from 12 to 48.
- 18 Jul 2017 Planned End Date changed from 6 Mar 2018 to 1 Mar 2018.
- 18 Jul 2017 Planned primary completion date changed from 25 Jan 2018 to 1 Jan 2018.